12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

N8295: Phase Ib data

An open-label, U.S. Phase Ib trial in 15 healthy volunteers showed that 3 doses of N8295 given a month apart plus an undisclosed investigational H5N1 avian influenza vaccine from Novartis AG (NYSE:NVS; SIX:NOVN, Basel,...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >